Promising anticancer activity of cromolyn in colon cancer: in vitro and in vivo analysis

ConclusionOur study showed that cromolyn is a selective and strong drug in inhibiting the proliferation of colon cancer cells. Based on our results, the efficacy of C in vitro analysis (MTT assays and apoptosis), as well as animal studies is competitive with the FDA-approved drug doxorubicin. C is very promising as a low-complication and good-efficacy drug for cancer drug repositioning. This requires clinical research study designs to comprehensively evaluate its anti-cancer effects.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research